Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.68 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.68 |
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423873 | 0.84 | CYP1A2 (0.68) | CYP1A2CYP2A6ACHEALDH1A1HPGD | |
| SCHEMBL18805057 | 0.84 | CYP1A2 (0.68) | CYP1A2CYP2A6ACHEALDH1A1HPGD | |
| SCHEMBL5015496 | 0.83 | CES2 (0.43) | CYP1A2CYP2A6ACHEALDH1A1HPGD | |
| SCHEMBL424167 | 0.83 | CYP1A2 (1.00) | CYP1A2CYP2A6ACHEALDH1A1HPGD | |
| SCHEMBL29618976 | 0.83 | CES2 (0.43) | CYP1A2CYP2A6ACHEALDH1A1HPGD | |
| SCHEMBL29463284 | 0.83 | CYP1A2 (1.00) | CYP1A2CYP2A6ACHEALDH1A1HPGD | |
| SCHEMBL19154348 | 0.78 | ACHE (0.48) | CYP1A2CYP2A6ACHEALDH1A1HPGD | |
| SCHEMBL19154007 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP2A6ACHEALDH1A1HPGD | |
| SCHEMBL12405315 | 0.77 | HPRT1 (0.48) | CYP1A2CYP2A6ACHEALDH1A1HPGD | |
| SCHEMBL599477 | 0.77 | CYP1A2 (0.87) | CYP1A2CYP2A6ACHEALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827616-B2 | Heterocyclic compounds as pesticides | DISCOVERY PURCHASER CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2023205719-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-4209492-A1 | COMPOUND FOR TREATING THROMBOTIC DISEASES | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2023-07-12 | — | — | EP | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11566016-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-31 | — | — | US | disclosed |
| US-11251376-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-02-15 | — | — | US | disclosed |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| US-11149020-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-10-19 | — | — | US | disclosed |
| US-11133473-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-09-28 | — | — | US | disclosed |
| EP-3842424-A1 | MAP KINASE MODULATORS AND USES THEREOF IN THE TRETAMENT OF TAUOPATHIES | The Trustees of Columbia University in the City of New York (US) | 2021-06-30 | — | — | EP | disclosed |
| US-6117893-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1022274-A1 | Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5886014-A | TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11133473-B2 | Condensed cyclic compound and organic light-emitting device including the same | C1S, C1R, CCNA1 | CYP1A2 985/4885CYP2A6 1803/4885ACHE 2958/4885 |
| US-11251376-B2 | Heterocyclic compound and organic light-emitting device including the same | LAGE3, DDT, AOC2 | CYP1A2 30/4885CYP2A6 897/4885ACHE 48/4885 |
| US-11566016-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | CYP1A2 4173/4885CYP2A6 4660/4885ACHE 650/4885 |
| US-11827616-B2 | Heterocyclic compounds as pesticides | DDT, CHRM1, ACHE | CYP1A2 110/4885CYP2A6 516/4885ACHE 3/4885 |
| US-11149020-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | CYP1A2 4173/4885CYP2A6 4660/4885ACHE 650/4885 |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | CYP1A2 4173/4885CYP2A6 4660/4885ACHE 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.